Cancer du canal anal: État des lieux, enjeux en oncogériatrie et thérapies moléculaires ciblées

Ngoc Hanh Hau Desbat; Pierre Auberdiac; Cyrus Chargari; Yacine Merrouche; Éric Deutsch; Thierry Schmitt; Guy De Laroche; Nicolas Magné

doi:10.1684/bdc.2011.1305

Cancer du canal anal: État des lieux, enjeux en oncogériatrie et thérapies moléculaires ciblées

Ngoc Hanh Hau Desbat, Pierre Auberdiac, Cyrus Chargari, Yacine Merrouche, Éric Deutsch, Thierry Schmitt, Guy De Laroche, Nicolas Magné

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

Résumé

Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy.

Titre traduit de la contribution	Carcinoma of the anal canal: State of art, issues in geriatric oncology and molecular targeted therapies
langue originale	Français
Pages (de - à)	146-153
Nombre de pages	8
journal	Bulletin du Cancer
Volume	98
Numéro de publication	2
Les DOIs	https://doi.org/10.1684/bdc.2011.1305
état	Publié - 1 janv. 2011

mots-clés

Anus neoplasm
EGFR
Molecular targeted therapies
Oncogeriatry
Radiochemotherapy

Accès au document

10.1684/bdc.2011.1305

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6dc0da021cd2478292774b2969824594,

title = "Cancer du canal anal: {\'E}tat des lieux, enjeux en oncog{\'e}riatrie et th{\'e}rapies mol{\'e}culaires cibl{\'e}es",

abstract = "Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy.",

keywords = "Anus neoplasm, EGFR, Molecular targeted therapies, Oncogeriatry, Radiochemotherapy",

author = "Desbat, {Ngoc Hanh Hau} and Pierre Auberdiac and Cyrus Chargari and Yacine Merrouche and {\'E}ric Deutsch and Thierry Schmitt and {De Laroche}, Guy and Nicolas Magn{\'e}",

year = "2011",

month = jan,

day = "1",

doi = "10.1684/bdc.2011.1305",

language = "Fran{\c c}ais",

volume = "98",

pages = "146--153",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "2",

}

TY - JOUR

T1 - Cancer du canal anal

T2 - État des lieux, enjeux en oncogériatrie et thérapies moléculaires ciblées

AU - Desbat, Ngoc Hanh Hau

AU - Auberdiac, Pierre

AU - Chargari, Cyrus

AU - Merrouche, Yacine

AU - Deutsch, Éric

AU - Schmitt, Thierry

AU - De Laroche, Guy

AU - Magné, Nicolas

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy.

AB - Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy.

KW - Anus neoplasm

KW - EGFR

KW - Molecular targeted therapies

KW - Oncogeriatry

KW - Radiochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=79953246836&partnerID=8YFLogxK

U2 - 10.1684/bdc.2011.1305

DO - 10.1684/bdc.2011.1305

M3 - Article 'review'

C2 - 21382795

AN - SCOPUS:79953246836

SN - 0007-4551

VL - 98

SP - 146

EP - 153

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 2

ER -